Creo Medical - New NHS client win for CROMA technology
In an encouraging development, Creo Medical has announced that Royal Oldham Hospital (UK) has become the latest NHS facility to sign up for its proprietary CROMA technology platform, Speedboat Inject (its flagship electrosurgical device) and related endotherapy products. Besides ordering several CROMA boxes and electrosurgical and associated devices to be used in submucosal dissection (SD) procedures, the hospital has shared its weekly list for planned Speedboat-assisted procedures, signalling ongoing commitment to Creo’s products and providing further validation of its platform and pipeline. The agreement indicates growing traction and acceptance of Speedboat Inject, which we expect to create further high-volume opportunities from other large network hospitals. With expansion of the Speedboat Inject user base (with an emphasis on training enrolment) being a strategic priority for FY23, we see this development as a step in the right direction.Creo Medical Group is a medical device company focused on the field of surgical endoscopy, a recent development in minimally invasive surgery. Co. is focused on developing and commercializing a suite of medical devices based on its CROMA electrosurgery platform.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.